HC Wainwright Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $221.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 23.29% from the stock’s current price.

KRYS has been the topic of several other reports. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Finally, Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $215.83.

Krystal Biotech Stock Up 3.4 %

Shares of NASDAQ:KRYS opened at $179.25 on Friday. Krystal Biotech has a 52-week low of $141.72 and a 52-week high of $219.34. The stock’s fifty day simple moving average is $159.41 and its 200-day simple moving average is $175.17. The company has a market capitalization of $5.16 billion, a P/E ratio of 59.95 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period in the prior year, the business earned $0.30 earnings per share. The business’s revenue was up 116.4% on a year-over-year basis. On average, sell-side analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of KRYS. US Bancorp DE grew its stake in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after buying an additional 82 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after buying an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after buying an additional 121 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock valued at $1,822,000 after buying an additional 121 shares in the last quarter. Finally, Perigon Wealth Management LLC grew its stake in shares of Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after buying an additional 123 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).